Perspective Therapeutics Net Income
| CATX Stock | 4.70 0.32 6.37% |
As of the 15th of February 2026, Perspective Therapeutics holds the Semi Deviation of 5.01, risk adjusted performance of 0.1312, and Coefficient Of Variation of 661.38. Perspective Therapeutics technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices.
Perspective Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 68.7327 | Revenue | Earnings Share (1.51) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -71.4 M | -67.8 M | |
| Net Loss | -70.5 M | -67 M | |
| Net Loss | -6.5 M | -6.9 M | |
| Net Loss | (1.11) | (1.05) | |
| Net Income Per E B T | 1.12 | 1.06 |
Perspective | Net Income | Build AI portfolio with Perspective Stock |
The evolution of Net Income for Perspective Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Perspective Therapeutics compares to historical norms and industry peers.
Latest Perspective Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Perspective Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Perspective Therapeutics financial statement analysis. It represents the amount of money remaining after all of Perspective Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Perspective Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Perspective Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (79.28 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Perspective Net Income Regression Statistics
| Arithmetic Mean | (19,371,114) | |
| Coefficient Of Variation | (142.62) | |
| Mean Deviation | 22,051,434 | |
| Median | (4,850,000) | |
| Standard Deviation | 27,626,599 | |
| Sample Variance | 763.2T | |
| Range | 78.8M | |
| R-Value | (0.77) | |
| Mean Square Error | 327.3T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | (4,230,405) | |
| Total Sum of Squares | 12211.7T |
Perspective Net Income History
Other Fundumenentals of Perspective Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Perspective Therapeutics Net Income component correlations
Perspective Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Perspective Therapeutics is extremely important. It helps to project a fair market value of Perspective Stock properly, considering its historical fundamentals such as Net Income. Since Perspective Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Perspective Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Perspective Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Perspective Therapeutics. Projected growth potential of Perspective fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Perspective Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.51) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of Perspective Therapeutics is measured differently than its book value, which is the value of Perspective that is recorded on the company's balance sheet. Investors also form their own opinion of Perspective Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Perspective Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Perspective Therapeutics' market value can be influenced by many factors that don't directly affect Perspective Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Perspective Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Perspective Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Perspective Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Perspective Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Perspective Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Perspective Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Perspective Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Perspective Therapeutics or generate 0.0% return on investment in Perspective Therapeutics over 90 days. Perspective Therapeutics is related to or competes with Profound Medical, TriSalus Life, Nyxoah, Helius Medical, Invivyd, MaxCyte, and Nano X. Perspective Therapeutics is entity of United States More
Perspective Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Perspective Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Perspective Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.49 | |||
| Information Ratio | 0.1444 | |||
| Maximum Drawdown | 77.44 | |||
| Value At Risk | (8.80) | |||
| Potential Upside | 8.14 |
Perspective Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Perspective Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Perspective Therapeutics' standard deviation. In reality, there are many statistical measures that can use Perspective Therapeutics historical prices to predict the future Perspective Therapeutics' volatility.| Risk Adjusted Performance | 0.1312 | |||
| Jensen Alpha | 1.47 | |||
| Total Risk Alpha | 0.7849 | |||
| Sortino Ratio | 0.2301 | |||
| Treynor Ratio | 1.18 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Perspective Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Perspective Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1312 | |||
| Market Risk Adjusted Performance | 1.19 | |||
| Mean Deviation | 5.2 | |||
| Semi Deviation | 5.01 | |||
| Downside Deviation | 6.49 | |||
| Coefficient Of Variation | 661.38 | |||
| Standard Deviation | 10.33 | |||
| Variance | 106.79 | |||
| Information Ratio | 0.1444 | |||
| Jensen Alpha | 1.47 | |||
| Total Risk Alpha | 0.7849 | |||
| Sortino Ratio | 0.2301 | |||
| Treynor Ratio | 1.18 | |||
| Maximum Drawdown | 77.44 | |||
| Value At Risk | (8.80) | |||
| Potential Upside | 8.14 | |||
| Downside Variance | 42.09 | |||
| Semi Variance | 25.11 | |||
| Expected Short fall | (5.68) | |||
| Skewness | 4.22 | |||
| Kurtosis | 24.82 |
Perspective Therapeutics Backtested Returns
Perspective Therapeutics is very risky given 3 months investment horizon. Perspective Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.16, which implies the firm had a 0.16 % return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.67% are justified by taking the suggested risk. Use Perspective Therapeutics Semi Deviation of 5.01, coefficient of variation of 661.38, and Risk Adjusted Performance of 0.1312 to evaluate company specific risk that cannot be diversified away. Perspective Therapeutics holds a performance score of 12 on a scale of zero to a hundred. The company holds a Beta of 1.32, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Perspective Therapeutics will likely underperform. Use Perspective Therapeutics value at risk, as well as the relationship between the kurtosis and market facilitation index , to analyze future returns on Perspective Therapeutics.
Auto-correlation | 0.83 |
Very good predictability
Perspective Therapeutics has very good predictability. Overlapping area represents the amount of predictability between Perspective Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Perspective Therapeutics price movement. The serial correlation of 0.83 indicates that around 83.0% of current Perspective Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.83 | |
| Spearman Rank Test | 0.61 | |
| Residual Average | 0.0 | |
| Price Variance | 1.15 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Perspective Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Perspective Therapeutics reported net income of (79.28 Million). This is 123.23% lower than that of the Health Care Equipment & Supplies sector and 179.57% lower than that of the Health Care industry. The net income for all United States stocks is 113.88% higher than that of the company.
Perspective Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Perspective Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Perspective Therapeutics could also be used in its relative valuation, which is a method of valuing Perspective Therapeutics by comparing valuation metrics of similar companies.Perspective Therapeutics is currently under evaluation in net income category among its peers.
Perspective Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Perspective Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Perspective Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Perspective Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (133.31) % | ||||
| Current Valuation | 364.57 M | ||||
| Shares Outstanding | 113.91 M | ||||
| Shares Owned By Insiders | 10.79 % | ||||
| Shares Owned By Institutions | 60.14 % | ||||
| Number Of Shares Shorted | 9.54 M | ||||
| Price To Book | 2.21 X | ||||
| Price To Sales | 498.04 X | ||||
| Gross Profit | (60.89 M) | ||||
| EBITDA | 10.46 M | ||||
| Net Income | (79.28 M) | ||||
| Total Debt | 4.06 M | ||||
| Book Value Per Share | 3.26 X | ||||
| Cash Flow From Operations | (18.29 M) | ||||
| Short Ratio | 1.88 X | ||||
| Earnings Per Share | (1.51) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 138 | ||||
| Beta | 1.79 | ||||
| Market Capitalization | 535.4 M | ||||
| Total Asset | 341.1 M | ||||
| Retained Earnings | (231.72 M) | ||||
| Working Capital | 212.93 M | ||||
| Net Asset | 341.1 M |
About Perspective Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Perspective Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Perspective Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Perspective Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.